Show simple item record

dc.contributor.authorPhillips, E
dc.contributor.authorJones, RL
dc.contributor.authorHuang, P
dc.contributor.authorDigklia, A
dc.date.accessioned2022-04-13T08:46:37Z
dc.date.available2022-04-13T08:46:37Z
dc.identifier.citationFrontiers in Pharmacology, 13en
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5078
dc.identifier.eissn1663-9812en_US
dc.identifier.eissn1663-9812
dc.identifier.doi10.3389/fphar.2022.869754en_US
dc.identifier.doi10.3389/fphar.2022.869754
dc.description.abstract<jats:p>Soft tissue sarcomas are a highly heterogenous group of tumors with limited systemic therapy options. Eribulin, a synthetic analogue of halichondrin B, is a potent mitotic inhibitor. A phase 3 trial of previously treated advanced Liposarcoma and Leiomyosarcoma demonstrated superiority of eribulin to dacarbazine. Eribulin appears to be particularly effective for liposarcomas. It has also been shown to be a safe and effective treatment alternative to doxorubicin in patients where doxorubicin is contraindicated. From retrospective studies, eribulin has demonstrated efficacy in patients with angiosarcoma, pleomorphic sarcomas, synovial sarcomas, rhabdomyosarcomas, angiosarcomas, and myxofibrosarcomas. Future areas of development include liposomal eribulin, which may provide increased efficacy and lower toxicity, and delineation of biomarkers of response and resistance, allowing better selection of patients for treatment.</jats:p>en_US
dc.language.isoengen
dc.publisherFrontiers Media SAen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.titleEfficacy of Eribulin in Soft Tissue Sarcomasen
dc.typeJournal Article
dcterms.dateAccepted2022-03-30
rioxxterms.versionVoRen
rioxxterms.versionofrecord10.3389/fphar.2022.869754en
dc.relation.isPartOfFrontiers in Pharmacologyen_US
pubs.notesNo embargoen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular and Systems Oncology
pubs.publication-statusPublished onlineen_US
pubs.volume13en_US
pubs.embargo.termsNo embargoen_US
icr.researchteamMolecular and Systems Oncology
dc.contributor.icrauthorHuang, Paulen_US


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/